Clinical Trials in San Francisco

Showing 1401-1420 of 6,211 trials

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

NCT04257110

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.

Locally Advanced/Metastatic HER2 Positive Solid Tumors

Bliss Biopharmaceutical (Hangzhou) Co., Ltd117 participantsStarted Jul 2020

San Francisco, California, United States • Nashville, Tennessee, United States • Fairfax, Virginia, United States +9 more locations

COMPLETEDPHASE3< 1 mile

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

NCT04026412

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb925 participantsStarted Oct 2019

La Jolla, California, United States • San Francisco, California, United States • San Francisco, California, United States +180 more locations

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Find Trials by Condition in San Francisco

Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Microsteps Study-Short, Animated Storytelling Video

Non-surgical Spinal Decompression Therapy and Outcomes

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Mindfulness-based Cognitive Coping for ADRD Caregivers

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD